Dirksen Lehman - Edwards Lifesciences Co Affairs
EWL Stock | EUR 70.08 0.26 0.37% |
Insider
Dirksen Lehman is Co Affairs of Edwards Lifesciences
Phone | 949 250 2500 |
Web | https://www.edwards.com |
Edwards Lifesciences Management Efficiency
The company has return on total asset (ROA) of 0.1334 % which means that it generated a profit of $0.1334 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2614 %, meaning that it generated $0.2614 on every $100 dollars invested by stockholders. Edwards Lifesciences' management efficiency ratios could be used to measure how well Edwards Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
Mary Moreland | Abbott Laboratories | 57 | |
Andrew Pierce | Stryker | 49 | |
Robert Cohen | Stryker | N/A | |
Marc Koebernick | Siemens Healthineers AG | N/A | |
Susan Lisa | Boston Scientific | 54 | |
Mark Ploof | Medtronic PLC | N/A | |
Jochen Schmitz | Siemens Healthineers AG | 57 | |
Jonathan Monson | Boston Scientific | N/A | |
Julie Coletti | Align Technology | 54 | |
Elisabeth Staudinger | Siemens Healthineers AG | 53 | |
Joseph Hogan | Align Technology | 66 | |
James Young | Abbott Laboratories | N/A | |
Shirley Stacy | Align Technology | N/A | |
Michel DVM | Siemens Healthineers AG | 62 | |
Christian Klaussner | Siemens Healthineers AG | N/A | |
Darleen Caron | Siemens Healthineers AG | 59 | |
Ivan Fong | Medtronic PLC | 62 | |
Catherine Jennings | Boston Scientific | N/A | |
Joseph Fitzgerald | Boston Scientific | 59 | |
John Sorenson | Boston Scientific | 55 | |
Melissa Brotz | Abbott Laboratories | N/A |
Management Performance
Return On Equity | 0.26 | |||
Return On Asset | 0.13 |
Edwards Lifesciences Leadership Team
Elected by the shareholders, the Edwards Lifesciences' board of directors comprises two types of representatives: Edwards Lifesciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Edwards. The board's role is to monitor Edwards Lifesciences' management team and ensure that shareholders' interests are well served. Edwards Lifesciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Edwards Lifesciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Scott Ullem, Co CFO | ||
Larry Wood, Co Replacement | ||
Mark Wilterding, VP Relations | ||
Donald Bobo, Corp Devel | ||
Todd Brinton, Co Officer | ||
Arnold Pinkston, Corp Counsel | ||
Dirksen Lehman, Co Affairs | ||
Michael Mussallem, Chairman CEO | ||
JeanLuc Lemercier, Middle Europe | ||
Christine McCauley, Co HR |
Edwards Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Edwards Lifesciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.26 | |||
Return On Asset | 0.13 | |||
Profit Margin | 0.28 % | |||
Operating Margin | 0.33 % | |||
Current Valuation | 43.48 B | |||
Shares Outstanding | 608.31 M | |||
Shares Owned By Insiders | 0.82 % | |||
Shares Owned By Institutions | 86.92 % | |||
Price To Earning | 45.19 X | |||
Price To Book | 7.49 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Edwards Stock
Edwards Lifesciences financial ratios help investors to determine whether Edwards Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Edwards with respect to the benefits of owning Edwards Lifesciences security.